Gilead Sciences (GILD) Revenue & Revenue Breakdown
Gilead Sciences Revenue Highlights
Latest Revenue (Y)
$27.12B
Latest Revenue (Q)
$6.95B
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Gilead Sciences Revenue by Period
Gilead Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $27.12B | -0.60% |
| 2022-12-31 | $27.28B | -0.09% |
| 2021-12-31 | $27.30B | 10.60% |
| 2020-12-31 | $24.69B | 9.98% |
| 2019-12-31 | $22.45B | 1.46% |
| 2018-12-31 | $22.13B | -15.24% |
| 2017-12-31 | $26.11B | -14.09% |
| 2016-12-31 | $30.39B | -6.89% |
| 2015-12-31 | $32.64B | 31.13% |
| 2014-12-31 | $24.89B | 122.20% |
| 2013-12-31 | $11.20B | 15.45% |
| 2012-12-31 | $9.70B | 15.71% |
| 2011-12-31 | $8.39B | 5.48% |
| 2010-12-31 | $7.95B | 13.38% |
| 2009-12-31 | $7.01B | 31.40% |
| 2008-12-31 | $5.34B | 26.14% |
| 2007-12-31 | $4.23B | 39.78% |
| 2006-12-31 | $3.03B | 49.19% |
| 2005-12-31 | $2.03B | 53.13% |
| 2004-12-31 | $1.32B | 52.63% |
| 2003-12-31 | $867.86M | 85.92% |
| 2002-12-31 | $466.79M | 99.68% |
| 2001-12-31 | $233.77M | 19.54% |
| 2000-12-31 | $195.56M | 15.71% |
| 1999-12-31 | $169.00M | 418.40% |
| 1998-12-31 | $32.60M | -18.50% |
| 1997-12-31 | $40.00M | 19.76% |
| 1996-12-31 | $33.40M | 1137.04% |
| 1995-12-31 | $2.70M | -34.15% |
| 1994-03-31 | $4.10M | -2.38% |
| 1993-03-31 | $4.20M | - |
Gilead Sciences generated $27.12B in revenue during NA 2023, up -0.60% compared to the previous quarter, and up 122.55% compared to the same period a year ago.
Gilead Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $6.95B | 4.01% |
| 2024-03-31 | $6.69B | -6.03% |
| 2023-12-31 | $7.12B | 0.92% |
| 2023-09-30 | $7.05B | 6.83% |
| 2023-06-30 | $6.60B | 3.89% |
| 2023-03-31 | $6.35B | -14.03% |
| 2022-12-31 | $7.39B | 4.93% |
| 2022-09-30 | $7.04B | 12.49% |
| 2022-06-30 | $6.26B | -5.01% |
| 2022-03-31 | $6.59B | -9.03% |
| 2021-12-31 | $7.24B | -2.39% |
| 2021-09-30 | $7.42B | 19.37% |
| 2021-06-30 | $6.22B | -3.21% |
| 2021-03-31 | $6.42B | -13.45% |
| 2020-12-31 | $7.42B | 12.83% |
| 2020-09-30 | $6.58B | 27.88% |
| 2020-06-30 | $5.14B | -7.30% |
| 2020-03-31 | $5.55B | -5.63% |
| 2019-12-31 | $5.88B | 4.91% |
| 2019-09-30 | $5.60B | -1.42% |
| 2019-06-30 | $5.68B | 7.65% |
| 2019-03-31 | $5.28B | -8.87% |
| 2018-12-31 | $5.79B | 3.56% |
| 2018-09-30 | $5.60B | -0.92% |
| 2018-06-30 | $5.65B | 11.01% |
| 2018-03-31 | $5.09B | -14.47% |
| 2017-12-31 | $5.95B | -8.65% |
| 2017-09-30 | $6.51B | -8.81% |
| 2017-06-30 | $7.14B | 9.78% |
| 2017-03-31 | $6.50B | -11.13% |
| 2016-12-31 | $7.32B | -2.40% |
| 2016-09-30 | $7.50B | -3.55% |
| 2016-06-30 | $7.78B | -0.23% |
| 2016-03-31 | $7.79B | -8.37% |
| 2015-12-31 | $8.51B | 2.54% |
| 2015-09-30 | $8.29B | 0.62% |
| 2015-06-30 | $8.24B | 8.56% |
| 2015-03-31 | $7.59B | 3.82% |
| 2014-12-31 | $7.31B | 21.06% |
| 2014-09-30 | $6.04B | -7.55% |
| 2014-06-30 | $6.53B | 30.73% |
| 2014-03-31 | $5.00B | 60.23% |
| 2013-12-31 | $3.12B | 12.11% |
| 2013-09-30 | $2.78B | 0.56% |
| 2013-06-30 | $2.77B | 9.31% |
| 2013-03-31 | $2.53B | -2.19% |
| 2012-12-31 | $2.59B | 6.66% |
| 2012-09-30 | $2.43B | 0.89% |
| 2012-06-30 | $2.41B | 5.38% |
| 2012-03-31 | $2.28B | 3.73% |
| 2011-12-31 | $2.20B | 3.71% |
| 2011-09-30 | $2.12B | -0.73% |
| 2011-06-30 | $2.14B | 10.96% |
| 2011-03-31 | $1.93B | -3.63% |
| 2010-12-31 | $2.00B | 3.15% |
| 2010-09-30 | $1.94B | 0.54% |
| 2010-06-30 | $1.93B | -7.60% |
| 2010-03-31 | $2.09B | 2.63% |
| 2009-12-31 | $2.03B | 12.82% |
| 2009-09-30 | $1.80B | 9.36% |
| 2009-06-30 | $1.65B | 7.62% |
| 2009-03-31 | $1.53B | 7.16% |
| 2008-12-31 | $1.43B | 4.15% |
| 2008-09-30 | $1.37B | 7.29% |
| 2008-06-30 | $1.28B | 1.59% |
| 2008-03-31 | $1.26B | - |
Gilead Sciences generated $6.95B in revenue during Q2 2024, up 4.01% compared to the previous quarter, and up 109.48% compared to the same period a year ago.
Gilead Sciences Revenue Breakdown
Gilead Sciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|
| Product | $26.93B | - | - | - |
| Royalty, Contract, And Other | $182.00M | $334.00M | $330.00M | $450.00M |
| Oncology Product | $2.93B | - | - | - |
Gilead Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (89.64%), Oncology Product (9.76%), and Royalty, Contract, And Other (0.61%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cell Therapy Products, Total Cell Therapy Product Sales | $960.00M | - | - | - | - | - | - | - | - | - |
| Products, Other HIV | $4.34B | $4.71B | - | - | - | - | - | - | - | - |
| Veklury | $555.00M | $719.00M | - | - | - | - | - | - | - | - |
| Other Products, Total Other product sales | $224.00M | $201.00M | - | - | - | - | - | - | - | - |
| Trodelvy | $309.00M | $298.00M | - | - | - | - | - | - | - | - |
| Oncology Product | - | $2.16B | $769.00M | - | - | - | - | - | - | - |
| Product | - | $19.94B | $6.99B | $6.49B | $5.07B | $5.47B | - | - | - | - |
| Royalty, Contract, And Other | - | $126.00M | $56.00M | $83.00M | $88.00M | $78.00M | $81.00M | - | - | - |
| Hepatitis B Virus / Hepatitis Delta Virus Product | - | $259.00M | - | - | - | - | - | - | - | - |
Gilead Sciences's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Products, Other HIV (67.95%), Cell Therapy Products, Total Cell Therapy Product Sales (15.02%), Veklury (8.69%), Trodelvy (4.84%), and Other Products, Total Other product sales (3.51%).
Gilead Sciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Europe | $4.31B | $702.00M | $1.09B | $241.00M | $244.00M |
| UNITED STATES | $19.44B | $1.57B | $3.64B | $76.00M | $80.00M |
Gilead Sciences's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (81.85%), and Europe (18.15%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe | $1.16B | $1.16B | $1.04B | $52.00M | $111.00M | $142.00M | $130.00M | $126.00M | $304.00M | $334.00M | $109.00M | $264.00M | $388.00M | $71.00M | $937.00M | $62.00M | $48.00M | $63.00M | $67.00M | $58.00M |
| Other International | $894.00M | $765.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| UNITED STATES | $4.63B | $5.18B | $5.02B | $189.00M | $252.00M | $396.00M | $336.00M | $41.00M | $801.00M | $877.00M | $1.53B | $416.00M | $820.00M | $21.00M | $24.00M | $14.00M | $17.00M | $19.00M | $20.00M | $4.07B |
Gilead Sciences's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (69.29%), Europe (17.33%), and Other International (13.37%).
Gilead Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JNJ | Johnson & Johnson | $85.15B | $22.45B |
| MRK | Merck | $60.12B | $16.11B |
| PFE | Pfizer | $58.50B | $13.28B |
| ABBV | AbbVie | $54.32B | $14.46B |
| AZN | AstraZeneca | $45.81B | $12.68B |
| BMY | Bristol-Myers Squibb Company | $45.01B | $12.20B |
| LLY | Eli Lilly and Company | $34.12B | $11.30B |
| AMGN | Amgen | $28.19B | $8.39B |
| GILD | Gilead Sciences | $27.12B | $6.95B |
GILD Revenue FAQ
What is Gilead Sciences’s yearly revenue?
Gilead Sciences's yearly revenue for 2023 was $27.12B, representing a decrease of -0.60% compared to 2022. The company's yearly revenue for 2022 was $27.28B, representing a decrease of -0.09% compared to 2021. GILD's yearly revenue for 2021 was $27.3B, representing an increase of 10.60% compared to 2020.
What is Gilead Sciences’s quarterly revenue?
Gilead Sciences's quarterly revenue for Q2 2024 was $6.95B, a 4.01% increase from the previous quarter (Q1 2024), and a 5.38% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $6.69B, a -6.03% decrease from the previous quarter (Q4 2023), and a 5.26% increase year-over-year (Q1 2023). GILD's quarterly revenue for Q4 2023 was $7.12B, a 0.92% increase from the previous quarter (Q3 2023), and a -3.71% decrease year-over-year (Q4 2022).
What is Gilead Sciences’s revenue growth rate?
Gilead Sciences's revenue growth rate for the last 3 years (2021-2023) was -0.69%, and for the last 5 years (2019-2023) was 20.79%.
What are Gilead Sciences’s revenue streams?
Gilead Sciences's revenue streams in c 23 are Product, Royalty, Contract, And Other, and Oncology Product. Product generated $26.93B in revenue, accounting 89.64% of the company's total revenue Royalty, Contract, And Other generated $182M in revenue, accounting 0.61% of the company's total revenue, down -45.51% year-over-year. Oncology Product generated $2.93B in revenue, accounting 9.76% of the company's total revenue
What is Gilead Sciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Gilead Sciences was Product. This segment made a revenue of $26.93B, representing 89.64% of the company's total revenue.